...
search icon
rnaz-img

Transcode Therapeutics Inc, Common Stock

RNAZ

NAQ

$8.075

-$1.29

(-13.77%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.52M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.0017
Volume info-icon
This is the total number of shares traded during the most recent trading day.
134.70K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.66 L
$66.33 H
$8.075

About Transcode Therapeutics Inc, Common Stock

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRNAZSectorS&P500
1-Week Return-23.65%1.67%0.11%
1-Month Return124.72%3.31%1.23%
3-Month Return-36.92%2.21%2.87%
6-Month Return-14.39%-4.82%8.93%
1-Year Return-64.22%1.22%22.83%
3-Year Return-99.99%15.75%42.13%
5-Year Return-99.99%42.34%83.14%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue--42.47K98.61K516.75K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":8.22,"profit":true},{"date":"2022-12-31","value":19.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit--(42.47K)(98.61K)(516.75K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-4247000,"profit":false},{"date":"2022-12-31","value":-9860600,"profit":false},{"date":"2023-12-31","value":-51674600,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses456.87K726.60K5.87M17.59M19.42M[{"date":"2019-12-31","value":2.35,"profit":true},{"date":"2020-12-31","value":3.74,"profit":true},{"date":"2021-12-31","value":30.24,"profit":true},{"date":"2022-12-31","value":90.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(456.87K)(726.60K)(6.15M)(18.67M)(19.42M)[{"date":"2019-12-31","value":-45686500,"profit":false},{"date":"2020-12-31","value":-72660400,"profit":false},{"date":"2021-12-31","value":-615113500,"profit":false},{"date":"2022-12-31","value":-1866581400,"profit":false},{"date":"2023-12-31","value":-1941851600,"profit":false}]
Total Non-Operating Income/Expense(307.28K)(2.01M)(786.67K)1.12M887.21K[{"date":"2019-12-31","value":-27.4,"profit":false},{"date":"2020-12-31","value":-179.42,"profit":false},{"date":"2021-12-31","value":-70.16,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.13,"profit":true}]
Pre-Tax Income(607.21K)(2.34M)(6.84M)(17.56M)(18.55M)[{"date":"2019-12-31","value":-60721200,"profit":false},{"date":"2020-12-31","value":-234389300,"profit":false},{"date":"2021-12-31","value":-684339900,"profit":false},{"date":"2022-12-31","value":-1756496800,"profit":false},{"date":"2023-12-31","value":-1854609500,"profit":false}]
Income Taxes156.93K394.44K95.07K17.56M4.00[{"date":"2019-12-31","value":0.89,"profit":true},{"date":"2020-12-31","value":2.25,"profit":true},{"date":"2021-12-31","value":0.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(764.14K)(2.74M)(6.94M)(35.13M)(18.55M)[{"date":"2019-12-31","value":-76414300,"profit":false},{"date":"2020-12-31","value":-273833000,"profit":false},{"date":"2021-12-31","value":-693846900,"profit":false},{"date":"2022-12-31","value":-3512993600,"profit":false},{"date":"2023-12-31","value":-1854609900,"profit":false}]
Income From Continuous Operations(607.21K)(2.34M)(6.84M)(17.56M)(19.59M)[{"date":"2019-12-31","value":-60721200,"profit":false},{"date":"2020-12-31","value":-234389300,"profit":false},{"date":"2021-12-31","value":-684339900,"profit":false},{"date":"2022-12-31","value":-1756496800,"profit":false},{"date":"2023-12-31","value":-1959260400,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(764.14K)(2.74M)(6.94M)(35.13M)(18.55M)[{"date":"2019-12-31","value":-76414300,"profit":false},{"date":"2020-12-31","value":-273833000,"profit":false},{"date":"2021-12-31","value":-693846900,"profit":false},{"date":"2022-12-31","value":-3512993600,"profit":false},{"date":"2023-12-31","value":-1854609500,"profit":false}]
EPS (Diluted)--0.08(1.31)(632.68)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1637.5,"profit":false},{"date":"2023-12-31","value":-790850.75,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RNAZ
Cash Ratio 0.82
Current Ratio 1.58

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RNAZ
ROA (LTM) -129.43%
ROE (LTM) -490.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RNAZ
Debt Ratio Lower is generally better. Negative is bad. 0.58
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.42

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RNAZ
Trailing PE 0.00
Forward PE NM
P/S (TTM) 0.00
P/B 4.16
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Transcode Therapeutics Inc share price today?

Transcode Therapeutics Inc (RNAZ) share price today is $8.075

Can Indians buy Transcode Therapeutics Inc shares?

Yes, Indians can buy shares of Transcode Therapeutics Inc (RNAZ) on Vested. To buy Transcode Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNAZ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Transcode Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Transcode Therapeutics Inc (RNAZ) via the Vested app. You can start investing in Transcode Therapeutics Inc (RNAZ) with a minimum investment of $1.

How to invest in Transcode Therapeutics Inc shares from India?

You can invest in shares of Transcode Therapeutics Inc (RNAZ) via Vested in three simple steps:

  • Click on Sign Up or Invest in RNAZ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Transcode Therapeutics Inc shares
What is Transcode Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Transcode Therapeutics Inc (RNAZ) is $66.33. The 52-week low price of Transcode Therapeutics Inc (RNAZ) is $2.66.

What is Transcode Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Transcode Therapeutics Inc (RNAZ) is 0.0017

What is Transcode Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Transcode Therapeutics Inc (RNAZ) is 4.16

What is the Market Cap of Transcode Therapeutics Inc?

The market capitalization of Transcode Therapeutics Inc (RNAZ) is $6.52M

What is Transcode Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Transcode Therapeutics Inc is RNAZ

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top